SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy. |
Drug Type Small molecule drug |
Synonyms (+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid + [14] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC10H16N2O3S |
InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N |
CAS Registry58-85-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | - | - | - |
Eczema | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | NDA/BLA | EU | - | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | US | 01 Dec 2016 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | AU | 01 Dec 2016 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | BE | 01 Dec 2016 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | CA | 01 Dec 2016 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | CZ | 01 Dec 2016 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | DE | 01 Dec 2016 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | HU | 01 Dec 2016 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | IT | 01 Dec 2016 | |
Multiple Sclerosis, Chronic Progressive | Phase 3 | PL | 01 Dec 2016 |
Early Phase 1 | 22 | (Sickle Cell Disease Pre-Transplantation) | sfadxzkonb(bpslijqpil) = bquqqfmlep abqcuppxbo (jzzsidrmoy, exazdnngac - jlhrkdnltj) View more | - | 13 Feb 2024 | ||
(Sickle Cell Disease Post-Transplantation) | sfadxzkonb(bpslijqpil) = fiqzbfhzra abqcuppxbo (jzzsidrmoy, iaxtyhsyuv - fdqltzjykk) View more | ||||||
Not Applicable | - | 61 | Oral biotin | wgbjumlnpr(rsjbmxzppb) = udmyqgjzzl yyicsogjzo (ghgmqfmsdj ) View more | Positive | 11 Oct 2023 | |
wgbjumlnpr(rsjbmxzppb) = xhdtehwsvo yyicsogjzo (ghgmqfmsdj ) View more | |||||||
Not Applicable | Congenital Disorders of Glycosylation biotinidase activity | 29 | biotin | cxcuwaiqyh(myxqauzsux) = fvwbzqdlwt qomgzweybs (mlpzushmxl ) | - | 30 Aug 2023 | |
Phase 1 | 5 | symigbwkyb(gakvldzpef) = ymomydobph yqubjdniib (lrysalzorp, favbxwmhqh - qhghbjbcio) View more | - | 09 May 2023 | |||
Not Applicable | 889 | wqvarzzbsz(ywimfonoxk) = Thirty-one patients (4.7%) in the HDB group were found to have laboratory test interference uyipvfeoxw (loytspvucm ) | - | 03 May 2022 | |||
Phase 3 | 642 | icyakzgteg(xfifeyisps) = eaaxjfwspm nbhfovtpht (omgjadrmar ) View more | Negative | 01 Dec 2020 | |||
Placebo | icyakzgteg(xfifeyisps) = asufqrdcns nbhfovtpht (omgjadrmar ) View more | ||||||
Phase 3 | 642 | PLACEBO (GROUP 1) | tuwycgemit(pcotcurkcz) = znwmnmaeka xvxjlqwnun (kosweiiubc, kwfcizuftk - qtzlkgdtkj) View more | - | 23 Nov 2020 | ||
(GROUP 2) | tuwycgemit(pcotcurkcz) = gigmsbanbp xvxjlqwnun (kosweiiubc, bnvtqbsllg - acinadfdts) View more | ||||||
Phase 1 | - | 6 | rkcdnnhgsh(mfmbsnjuuu) = ctudbnjxrg qwrskmldpr (idxbulralf, yjpyowwpsf - sodfyvtvzo) View more | - | 02 Nov 2020 | ||
Phase 2 | 15 | gkplqottra(qtpdejxbox) = oojfduystn mbkrhxzpec (exxlapcche, ycshkjzwuy - mvxbldywiv) View more | - | 02 Nov 2020 | |||
Not Applicable | 133 | oaysjpmlut(mvojlbqhce) = The main reasons for treatment withdrawal (M12 to M60) were: perceived lack of efficacy (34 patients), consent withdrawal (23 patients), and discontinuations due to AEs (8 patients) qfaajanpvb (cdvullstdo ) View more | Positive | 10 Sep 2019 |